非诺贝特在初治原发性胆汁性胆管炎患者中的疗效:一项随机临床试验
该随机、平行、开放标签临床试验纳入117例初治原发性胆汁性胆管炎(PBC)患者,比较熊去氧胆酸(UDCA)标准剂量单药与联合非诺贝特每日200mg治疗12个月的疗效。结果显示联合组巴塞罗那标准生化应答率81.4%(69.9%-92.9%),单药组64.3%(51.9%-76.8%),P=0.048;两组除碱性磷酸酶外的无创肝纤维化指标及其他生化标志物无差异。
要点
- 初治PBC患者中,非诺贝特联合UDCA较UDCA单药显著提高12个月巴塞罗那标准生化应答率(81.4% vs 64.3%,P=0.048)。
- 联合组肌酐和转氨酶在第一个月内升高,随后恢复正常并保持稳定至研究结束,肝硬化患者亦如此。
- 两组除碱性磷酸酶外的无创肝纤维化指标及其他生化标志物在12个月时无差异。
核心结论
- 在初治PBC患者中,非诺贝特联合UDCA较UDCA单药显著提高生化应答率,非诺贝特似乎耐受良好。
研究设计与样本
- 随机、平行、开放标签临床试验,自西京医院招募117例初治PBC患者,疗程12个月。
- 患者分为UDCA标准剂量单药组(UDCA-only组)或UDCA联合非诺贝特每日200mg组(UDCA-Fenofibrate组)。
主要发现
- 12个月时巴塞罗那标准生化应答率:UDCA-Fenofibrate组81.4%(69.9%-92.9%)vs UDCA-only组64.3%(51.9%-76.8%),P=0.048。
- 12个月时两组除碱性磷酸酶外的无创肝纤维化指标及其他生化标志物无差异。
- UDCA-Fenofibrate组肌酐和转氨酶水平在第一个月内升高,随后恢复正常并保持稳定至研究结束,肝硬化患者亦如此。
关键数值与推荐
- 主要结局为12个月时巴塞罗那标准生化应答率:UDCA-Fenofibrate组81.4%(69.9%-92.9%)vs UDCA-only组64.3%(51.9%-76.8%),P=0.048。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease, and patients with inadequate response to ursodeoxycholic acid (UDCA) treatment show reduced long-term survival. Recent studies have shown that fenofibrate is an effective off-label therapy for PBC. However, prospective studies on biochemical response including the timing of fenofibrate administration are lacking. This study is aimed to evaluate the efficacy and safety of fenofibrate in UDCA treatment-naive patients with PBC. METHODS: A total of 117 treatment-naive patients with PBC were recruited from the Xijing Hospital for a 12-month randomized, parallel, and open-label clinical trial. Study participants were assigned to receive either UDCA standard dose (UDCA-only group) or fenofibrate at a daily dose of 200 mg in addition to UDCA (UDCA-Fenofibrate group). RESULTS: The primary outcome was biochemical response percentage in patients according to the Barcelona criterion at 12 months. In the UDCA-Fenofibrate group, 81.4% (69.9%-92.9%) of patients achieved the primary outcome and 64.3% (51.9%-76.8%) in the UDCA-only group achieved the primary outcome ( P = 0.048). There was no difference between the 2 groups in noninvasive measures of liver fibrosis and biochemical markers other than alkaline phosphatase at 12 months. Creatinine and transaminases levels in the UDCA-Fenofibrate group increased within the first month, then returned to normal, and remained stable thereafter until the end of the study, even in patients with cirrhosis. DISCUSSION: In this randomized clinical trial in treatment-naive patients with PBC, the combination of fenofibrate and UDCA resulted in a significantly higher biochemical response rate. Fenofibrate seemed to be well-tolerated in patients.
引用
- Liu Y, Guo G, Zheng L, et al. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial. Am J Gastroenterol. 2023. PMID: 36892506. doi:10.14309/ajg.0000000000002238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。